Training and Resources – HIV Treatment Q&A with Dr Laura Waters
Training and Resources – HIV Treatment Q&A with Dr Laura Waters
DELSTRIGO®▼ (doravirine/3TC/TDF)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PIFELTRO®▼ (doravirine)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Licensed indication
PIFELTRO®▼ (doravirine) 100 mg film-coated tablet is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older, weighing at least 35 kg, infected with HIV-1, without past or present evidence of resistance to the NNRTI class.
DELSTRIGO®▼ (100 mg doravirine/300 mg lamivudine/300 mg tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil) is indicated for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine or tenofovir.
DELSTRIGO®▼ is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg, who are infected with HIV-1, without the past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.
Please consult the SmPC for further information before making any prescribing decisions.
Filming fully organised and funded by MSD, including speaker’s honoraria. Views of the speaker are their own and do not represent the opinions of MSD.
Want to watch the rest of this video series?
Register/login to watch more short videos featuring Dr. Laura Waters, consultant physician at the Mortimer Market Centre, answering a series of questions on doravirine, a next generation NNRTI, including sharing information on the NHS England procurement framework
This module is CPD certified, offering a certificate upon completion.
Abbreviations
ART: AntiRetroviral Therapy; NNRTIs: Non-Nucleoside Reverse Transcriptase Inhibitors
